This clinical trial, sponsored by Hospital Regional de Alta Especialidad del Bajio, investigates the effects of metformin on inflammatory mediators in obese adolescents with insulin resistance. The increasing prevalence of obesity and associated metabolic disorders in pediatric populations presents a significant market opportunity for treatments targeting insulin resistance and inflammation. Metformin, a well-established drug, is already used for diabetes management, which may facilitate its acceptance in this new indication. The competitive landscape includes lifestyle interventions and other pharmacological agents, but metformin's established safety profile and efficacy in reducing insulin resistance may provide a competitive edge. Diligence should focus on regulatory pathways and potential market access challenges in pediatric populations.